Tyme (TYME) 10-Q 8 Nov 21 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2021	Nov. 03, 2021
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	TYME
Entity Registrant Name	TYME TECHNOLOGIES, INC.
Entity Central Index Key	0001537917
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		172,206,894
Entity Address, Address Line One	1 Pluckemin Way – Suite 103
Entity Address, City or Town	Bedminster
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07921
City Area Code	212
Local Phone Number	461-2315
Entity Shell Company	false
Entity File Number	001-38169
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-3864597
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Current Assets
Cash and cash equivalents	$ 29,215,611	$ 107,516,420
Marketable securities	46,294,783
Prepaid clinical costs	560,098	987,470
Prepaid expenses and other current assets	1,309,366	1,152,970
Total current assets	77,379,858	109,656,860
Prepaid clinical costs, net of current portion		530,989
Operating lease right-of-use asset	57,396	75,471
Marketable securities	20,369,388
Total assets	97,806,642	110,263,320
Current liabilities
Accounts payable and other current liabilities (including $68,000 and $87,000 of related party accounts payable, respectively)	3,339,131	3,842,390
Severance payable	653,295	726,027
Accrued bonuses	741,197	1,040,710
Operating lease liability	38,883	34,658
Total current liabilities	4,772,506	5,643,785
Long-term liabilities
Severance payable, net of current portion	642,958	850,709
Operating lease liability, net of current portion	19,267	41,256
Warrant liability	862,612	1,931,921
Total liabilities	6,297,343	8,467,671
Commitments and contingencies (see Note 9)
Stockholders' equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 172,206,894 issued and outstanding at September 30, 2021, 300,000,000 authorized, 172,200,644 issued and outstanding at March 31, 2021	17,223	17,222
Additional paid in capital	239,838,521	238,572,442
Accumulated other comprehensive loss	(58,557)
Accumulated deficit	(148,287,888)	(136,794,015)
Total stockholders' equity	91,509,299	101,795,649
Total liabilities and stockholders' equity	$ 97,806,642	$ 110,263,320

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	172,206,894	172,200,644
Common stock, outstanding	172,206,894	172,200,644
Drinker, Biddle & Reath LLP ("DBR") [Member]
Related party accounts payable	$ 68,000	$ 87,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	3,495,416	4,707,448	7,679,827	9,422,743
General and administrative (including $151,000, $138,000, $266,000 and $341,000 of related party legal expenses, respectively)	2,433,099	2,613,689	4,901,258	5,670,761
Total operating expenses	5,928,515	7,321,137	12,581,085	15,093,504
Loss from operations	(5,928,515)	(7,321,137)	(12,581,085)	(15,093,504)
Other income (expense):
Change in fair value of warrant liability	344,166	489,572	1,069,309	(2,773,699)
Gain on warrant exchange				2,228,697
Other income	39,007	7,011	58,530	17,513
Interest expense	(19,368)	(25,980)	(40,627)	(55,356)
Total other income (expense)	363,805	470,603	1,087,212	(582,845)
Net loss	$ (5,564,710)	$ (6,850,534)	$ (11,493,873)	$ (15,676,349)
Basic and diluted loss per common share	$ (0.03)	$ (0.05)	$ (0.07)	$ (0.12)
Basic and diluted weighted average shares outstanding	172,206,894	128,046,895	172,206,177	126,323,921
Statements of Comprehensive Loss
Net loss	$ (5,564,710)	$ (6,850,534)	$ (11,493,873)	$ (15,676,349)
Other comprehensive loss
Unrealized loss on marketable securities, net of tax	(24,715)		(58,557)
Comprehensive loss	$ (5,589,425)	$ (6,850,534)	$ (11,552,430)	$ (15,676,349)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Related party legal expenses	$ 151,000	$ 138,000	$ 266,000	$ 341,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	At-the-Market Financing Facility [Member]	Common Stock [Member]	Common Stock [Member]At-the-Market Financing Facility [Member]	Additional Paid-in capital [Member]	Additional Paid-in capital [Member]At-the-Market Financing Facility [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance, at beginning at Mar. 31, 2020	$ 19,025,136		$ 12,333		$ 126,828,055		$ (107,815,252)
Balance, at beginning (in shares) at Mar. 31, 2020			123,312,252
Issuance of common stock		$ 1,171,586		$ 89		$ 1,171,497
Issuance of common stock (In shares)				891,944
Warrant to share exchange	3,393,775		$ 241		3,393,534
Warrant to share exchange (in shares)			2,406,250
Stock based compensation	1,068,696				1,068,696
Net loss	(8,825,815)						(8,825,815)
Balance, at end at Jun. 30, 2020	15,833,378		$ 12,663		132,461,782		(116,641,067)
Balance, at end (in shares) at Jun. 30, 2020			126,610,446
Balance, at beginning at Mar. 31, 2020	19,025,136		$ 12,333		126,828,055		(107,815,252)
Balance, at beginning (in shares) at Mar. 31, 2020			123,312,252
Net loss	(15,676,349)
Balance, at end at Sep. 30, 2020	14,501,321		$ 13,019		137,979,903		(123,491,601)
Balance, at end (in shares) at Sep. 30, 2020			130,172,441
Balance, at beginning at Jun. 30, 2020	15,833,378		$ 12,663		132,461,782		(116,641,067)
Balance, at beginning (in shares) at Jun. 30, 2020			126,610,446
Issuance of common stock		$ 4,634,548		$ 356		$ 4,634,192
Issuance of common stock (In shares)				3,561,995
Stock based compensation	883,929				883,929
Net loss	(6,850,534)						(6,850,534)
Balance, at end at Sep. 30, 2020	14,501,321		$ 13,019		137,979,903		(123,491,601)
Balance, at end (in shares) at Sep. 30, 2020			130,172,441
Balance, at beginning at Mar. 31, 2021	$ 101,795,649		$ 17,222		238,572,442		(136,794,015)
Balance, at beginning (in shares) at Mar. 31, 2021	172,200,644		172,200,644
Proceeds from the exercise of stock options	$ 6,188		$ 1		6,187
Proceeds from the exercise of stock options (in shares)			6,250
Stock based compensation	643,665				643,665
Unrealized loss on available-for-sale securities	(33,842)							$ (33,842)
Net loss	(5,929,163)						(5,929,163)
Balance, at end at Jun. 30, 2021	96,482,497		$ 17,223		239,222,294		(142,723,178)	(33,842)
Balance, at end (in shares) at Jun. 30, 2021			172,206,894
Balance, at beginning at Mar. 31, 2021	$ 101,795,649		$ 17,222		238,572,442		(136,794,015)
Balance, at beginning (in shares) at Mar. 31, 2021	172,200,644		172,200,644
Proceeds from the exercise of stock options (in shares)	6,250
Net loss	$ (11,493,873)
Balance, at end at Sep. 30, 2021	$ 91,509,299		$ 17,223		239,838,521		(148,287,888)	(58,557)
Balance, at end (in shares) at Sep. 30, 2021	172,206,894		172,206,894
Balance, at beginning at Jun. 30, 2021	$ 96,482,497		$ 17,223		239,222,294		(142,723,178)	(33,842)
Balance, at beginning (in shares) at Jun. 30, 2021			172,206,894
Stock based compensation	616,227				616,227
Unrealized loss on available-for-sale securities	(24,715)							(24,715)
Net loss	(5,564,710)						(5,564,710)
Balance, at end at Sep. 30, 2021	$ 91,509,299		$ 17,223		$ 239,838,521		$ (148,287,888)	$ (58,557)
Balance, at end (in shares) at Sep. 30, 2021	172,206,894		172,206,894

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
At-the-Market Financing Facility [Member]
Offering expense	$ 166,918	$ 120,790

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (11,493,873)	$ (15,676,349)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		2,590
Amortization of employees, directors and consultants stock options	1,259,892	1,952,625
Change in fair value of warrant liability	(1,069,309)	2,773,699
Gain on warrant exchange		(2,228,697)
Net amortization of premiums and discounts on marketable securities	722,493
Gain on call redemption of marketable securities	(109)
Change in operating assets and liabilities:
Prepaid clinical costs	958,361	(535,376)
Prepaid expenses and other assets	425,138	500,304
Operating lease right-of-use asset	18,075	132,974
Accounts payable and other current liabilities	(503,259)	1,550,056
Severance payable	(280,483)	(183,906)
Accrued bonuses	(299,513)	(1,017,189)
Operating lease liability	(17,764)	(34,830)
Net cash used in operating activities	(10,280,351)	(12,764,099)
Cash flows from investing activities
Purchases of marketable securities	(74,516,729)
Proceeds from maturities of marketable securities	6,490,083
Net cash used in investing activities	(68,026,646)
Cash flows from financing activities
Insurance note payments		(343,374)
Proceeds from registered offerings, net of issuance costs		5,806,134
Proceeds from exercise of stock options	6,188
Net cash provided by financing activities	6,188	5,462,760
Net decrease in cash and cash equivalents	(78,300,809)	(7,301,339)
Cash and cash equivalents – beginning	107,516,420	26,700,416
Cash and cash equivalents – ending	29,215,611	19,399,077
Supplemental Cash Flow Information:
Interest	$ 40,627	$ 55,356

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical)	6 Months Ended
	Sep. 30, 2020shares
Share Exchange Agreements [Member]
Cashless exchange of warrants to purchase	5,833,333
Cashless exchange of shares of common stock	2,406,250
Warrant Exchange Agreements [Member]
Cashless exchange of warrants to purchase	2,166,667

Nature of Business

Nature of Business	6 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of Business Tyme Technologies, Inc. is a Delaware corporation headquartered in Bedminster, New Jersey, with a wholly-owned subsidiary, Tyme Inc. (together, “TYME” or the “Company”). The majority of the Company’s research, development and other business activities are conducted by Tyme Inc., which was incorporated in Delaware in 2013. TYME is an emerging biotechnology company developing CMBTs TM The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline. Ongoing Studies Precision Promise Trial- SM-88 with MPS as 2 nd The Company has partnered with PanCAN to study SM-88 in an adaptive randomized Phase II/III trial with registration intent known as Precision Promise SM Although we do not have details of the enrollment of the SM-88 cohort, the next likely event in the trial would be a determination of potential “graduation” from the Phase II portion of the trial to the Phase III confirmatory portion of the trial. We expect to learn if the trial advances to Phase III during the second half of calendar year 2022. OASIS Trial in metastatic HR+/HER2- breast cancer This quarter, the Company announced an agreement with Georgetown University to support a Phase II trial, OASIS, for SM-88 in patients with metastatic breast cancer who have HR+ and HER2- disease (“HR+/HER2-”) . This represents approximately 73% of the annual breast cancer diagnoses in the US each year. The OASIS trial is an investigator-initiated prospective open-label Phase II trial evaluating the efficacy and safety of SM-88 with MPS for the treatment of metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor. This trial is designed as a two-stage trial, enrolling up to 50 patients to receive SM-88 with MPS without additional therapies in patients who have failed or progressed after receiving two hormonal agents and a CDK4/6 inhibitor. The primary endpoint of this trial is ORR, with secondary endpoints including DOR, CBR at >24 weeks, PFS, and safety. The trial will be conducted at Georgetown University at a total of five sites within the Georgetown/MEDSTAR system located in Washington DC, Maryland, and New Jersey. Patient enrollment began this quarter with the first patient dosed in September. We plan to provide an update on the OASIS breast cancer study during the first half of calendar year 2023. HoPES Trial in sarcoma In early 2020, the open-label Phase 2 investigator-sponsored trial of SM-88 therapy in sarcoma, HoPES, opened. This trial has two cohorts, each expecting to enroll 12 patients. The first is SM-88 with MPS as salvage treatment in patients with mixed rare sarcomas, and the other is SM-88 with MPS as maintenance treatment for patients with metastatic Ewing’s sarcoma who had not progressed on prior therapy. The primary objectives are to measure ORR and PFS. Secondary objectives include DOR, OS, CBR using RECIST, and incidence of treatment-emergent AEs. The Joseph Ahmed Foundation is sponsoring this trial and the trial is being conducted by PI Dr. Chawla at the Sarcoma Oncology Center in Santa Monica, CA. We anticipate that the trial will complete enrollment by the end of the first half of calendar year 2022. Preclinical Pipeline Programs The Company has begun a comprehensive translational preclinical program focused on SM-88 MOA and Biomarker Identification/Validation. We have engaged Evotec, a leading global research and development company, to aid in the execution of these activities and are also incorporating several complementary academic collaborations into this multi-faceted program. The overall goal of these activities is to potentially identify actionable biomarkers of sensitivity and activity to SM-88 in various cancers, complementary combination drugs strategies for SM-88, and other cancer metabolism targets that could be targeted for treatment. Later in the program, the Company intends to incorporate liquid and tumor biopsies into future clinical trials to contribute to the biomarker identification. TYME anticipates this preclinical engagement will have several stages, and that it is likely to last through this fiscal year and also into future periods. TYME-18 is a CMBT compound under development that is delivered intratumorally. TYME-18 leverages a member of the bile acid family to create a potential treatment for inoperable tumors. Preliminary observations of the local administration of TYME-18, a combination of a proprietary surfactant system and natural sulfonic acid, suggested its potential as an important regulator of energy metabolism that may impede the ability of tumors to increase in size, which, in addition to its lytic functionality, could prove useful in difficult-to-treat cancers. In initial preclinical xenograft mouse studies, TYME-18 was able to completely resolve over 90 percent (11/12 mice) of established colorectal tumors within 12 days versus an average of over 600 percent growth in the control animals. TYME-19 is an oral synthetic member of the bile acid family. The Company also uses bile acids in its anticancer drug candidate, TYME-18. Because of its expertise in bile acids and their effects, the Company was able to identify TYME-19 as a well-characterized bile acid with potential antiviral properties. Bile acids have primarily been used for liver disease; however, like all steroids, they are messenger molecules that modulate a number of diverse critical cellular processes. Bile acids can modulate lipid and glucose metabolism and can remediate dysregulated protein folding, with potentially therapeutic effects on cardiovascular, neurologic, immune, and other metabolic systems. Some agents in this class have also previously shown antiviral properties. In in vitro preclinical testing, TYME-19 prevented COVID-19 viral replication at doses without meaningful cytotoxicity to the treated cells. Previous independent preclinical research has also shown select bile acids may have had broad antiviral activity. Tumor Targeting Technology TYME has developed a technology (“Tumor Targeting Technology”) by which the tyrosine isomer L metyrosine (L-α-methylparatyrosine) can be fused with a second therapeutic agent in a manner that creates a fusion compound that may allow targeted accumulation of the treatment by the cancer cells in a novel manner. This method of tumor targeting is predicated on the metabolic phenomenon in which cancer cells consume higher quantities of non-essential amino acids, including tyrosine, from their surrounding environment to support their growth because they cannot make enough of these amino acids. Tumor Targeting Technology is an investigational approach in the preclinical phase of development that is not approved in the U.S. for any disease indication and requires further preclinical development, which the Company plans to initiate this year. Discontinuing Programs TYME-88-PANC (Part 2) (third-line Metastatic Pancreatic Cancer) In fiscal year 2020, TYME launched its pivotal study for SM-88 in the third-line treatment of pancreatic cancer through an amendment to our ongoing TYME-88-Panc trial (Part 2), with the first patient dosed in the third quarter of the fiscal year. As described previously, the COVID-19 pandemic significantly impacted enrollment of this trial such that it appeared it was likely to complete enrollment in a similar timeline to the second-line Precision Promise pancreatic cancer trial. There was also a higher than expected dropout rate of patients randomized to the chemotherapy control arm, which could have potentially impacted the interpretative and regulatory utility of the data. Following the strategic review discussed below, considering, in part, the timeline and regulatory utility for this trial compared to the parallel Precision Promise trial and concentration of investment in this specific cancer, management concluded that it would be best to focus on the second-line Precision Promise trial, which offers treatment options to patients earlier in their disease and includes tumor biopsy and biomarker analyses that align with the Company’s overall strategic focus on identifying targeted therapies. Therefore, the Company decided to stop enrollment and begin the process of closing down the trial. Patients currently on therapy will be allowed to continue treatment until progression or unacceptable toxicity. The closing of this trial is expected to require several months to complete. In the six months ended September 30, 2021, the Company expensed $843,000 of estimated closeout costs. The trial’s remaining ongoing expense to the Company is approximately $1.2 million, and is expected to be incurred over the next nine months. Liquidity The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. In February 2021, the Company raised $100 million in gross proceeds through a registered direct offering of 40,000,000 shares of its common stock, at a purchase price of $2.50 per share. The Company incurred $6.2 million of related costs, which offset such proceeds. On January 7, 2020, the Company entered into an SPA with Eagle Pharmaceuticals, Inc. (“Eagle”), pursuant to which the Company raised $20.0 million through the issuance and sale to Eagle of 10,000,000 shares of common stock, at a price of $2.00 per share. On October 18, 2019, TYME entered into an Open Market Sale Agreement SM The proceeds of the aforementioned offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses. For the six months ended September 30, 2021, the Company had negative cash flow from operations of $10.3 million and net loss of $11.5 million, which included non-cash expenses of $1.3 million related to non-cash equity compensation and $0.7 million net amortization expense of premiums and discounts on marketable securities, offset by $1.1 million income change in fair value of warrant liability. As of September 30, 2021, the Company had working capital of approximately $72.6 million. Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements . This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 filed with the SEC on June 10, 2021 (the “2021 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiary, Tyme Inc. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in ASC and ASU of the FASB. Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2021 included in the Company’s 2021 10-K. Cash and cash equivalents Cash and cash equivalents include demand deposit accounts, money market funds and municipal debt securities. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value. Marketable Securities All of the Company's marketable securities are debt securities and are classified as available-for-sale in accordance with the ASC Topic 320, “Investments - Debt and Equity Securities.” Available for sale securities are carried at fair value and reported in cash equivalents and marketable securities. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for a credit loss is recorded on our consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Fair Value of Financial Instruments The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. Cash equivalents, marketable securities and the derivative warrant liability are recorded at fair value. Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets (Level 1), and the lowest priority to unobservable inputs (Level 3). The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and their applicability to the Company’s financial assets, are described below. Level 1 : Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. Level 2 : Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. Level 3 : Pricing inputs are unobservable for the assets. Level 3 assets include private investments that are supported by little or no market activity. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis see Note 6 . Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise or certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the condensed consolidated statement of operations. As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features that cause the warrants to be treated as derivatives or requires the issuance of registered common shares upon exercise. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black-Scholes model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants (see Note 6). Risks and Uncertainties The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions The novel coronavirus (COVID-19) pandemic, and actions taken by governments and others to reduce its spread, has negatively impacted the global economy, financial markets, and the Company’s industry and has disrupted day-to-day life and business operations. Even as certain restrictions have been lifted, new processes implemented and vaccines have become more widely available and administered, spikes in infections (including the spread of new variants) continue to be experienced as conditions evolve and fluctuate around the world. The extent to which the continuing COVID-19 pandemic impacts our product candidates and business, including patients’ willingness to participate and remain in clinical trials, the timing of meeting enrollment expectations, the ability of our third-party partners to remain operational and our access to capital markets and financing sources, depends on numerous evolving factors that are highly uncertain, cannot be accurately predicted, and may be significant. Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Income Taxes In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) The amendments in ASU No. 2020-06 are effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. FASB also specified that an entity should adopt the guidance as of the beginning of its annual fiscal year and is not permitted to adopt the guidance in an interim period. The Company adopted the pronouncement as of April 1, 2021 and the adoption of this standard did not have a material impact on its condensed consolidated financial statements and disclosures.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 3. Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Basic and diluted net loss per common share calculation: Net loss $ (5,564,710 ) $ (6,850,534 ) $ (11,493,873 ) $ (15,676,349 ) Weighted average common shares outstanding — basic and diluted: 172,206,894 128,046,895 172,206,177 126,323,921 Net loss per share of common stock — basic and diluted $ (0.03 ) $ (0.05 ) $ (0.07 ) $ (0.12 ) The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic net loss per share is computed by dividing net loss attributable to the Company by the weighted average number of shares of Company Common Stock outstanding for the period, and diluted EPS is computed by including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive. The following outstanding securities at September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: September 30, 2021 2020 Stock options 14,697,448 14,577,732 Warrants 3,104,318 3,104,318 Total 17,801,766 17,682,050

Accounts Payable and Other Curr

Accounts Payable and Other Current Liabilities	6 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accounts Payable and Other Current Liabilities	Note 4. Accounts Payable and Other Current Liabilities Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: September 30, 2021 March 31, 2021 Legal $ 147,596 $ 454,139 Consultant and professional services 65,679 176,957 Accounting and auditing 2,822 55,349 Research and development 2,662,905 2,657,202 Board of Directors and Scientific Advisory Board Compensation 429,281 435,594 Other 30,848 63,149 Total $ 3,339,131 $ 3,842,390

Severance Payable

Severance Payable	6 Months Ended
	Sep. 30, 2021
Severance Payable [Abstract]
Severance Payable	Note 5. Severance Payable During the six months ended September 30, 2021, the Company entered into Separation and General Release Agreements with two employees. The agreements provide separation benefits which the Company recorded as severance expense. In April 2021, the Company entered into a Separation and General Release Agreement related to the separation of employment of its then-Chief Medical Officer as of March 31, 2021. The agreement provides for separation benefits which the Company recorded as severance expense for the year ended March 31, 2021. On March 15, 2019, the Company entered into a Release Agreement related to the separation of employment of its then-Chief Operating Officer. The agreement provides for salary continuance for five years, reimbursement of health benefits for three years and a modification to his outstanding stock options to extend the post-termination exercise period for his vested options from three months to five years. The Company recorded severance expense at its present value of $2.5 million (using a discount rate of 6%) for the year ended March 31, 2019, including $0.4 million relating to the stock option modification. The aggregate severance liability payable as of September 30, 2021 and March 31, 2021 was $1.3 million and $1.6 million, respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements The Company’s financial instruments measured at fair value on a recurring basis as of September 30, 2021 and March 31, 2021 are as follows: Quoted prices in active markets Significant other observable inputs Significant unobservable inputs September 30, 2021 Total (Level 1) (Level 2) (Level 3) Financial assets Cash equivalents Money market funds $ 6,726,462 $ 6,726,462 $ — $ — Marketable Securities Short-term Corporate debt securities 16,267,438 — 16,267,438 — Municipal debt securities 30,027,345 — 30,027,345 — Long-term Corporate debt securities 7,383,159 — 7,383,159 — Municipal debt securities 12,986,229 — 12,986,229 — $ 73,390,633 $ 6,726,462 $ 66,664,171 $ — Financial liability Warrant liability $ 862,612 $ — $ — $ 862,612 March 31, 2021 Financial liability Warrant liability $ 1,931,921 $ — $ — $ 1,931,921 Fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The fair value of cash equivalents held in money market funds is determined based on “Level 1” inputs. Marketable securities classified as Level 2 within the valuation hierarchy consist of corporate debt securities and municipal debt securities. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The fair value measurement for the warrant issued in conjunction with the Exchange Agreements (see Note 8 for transaction details) (the “May 2020 Warrant”) is based on significant inputs not observable in the market and is classified as Level 3 liability as of September 30, 2021 and March 31, 2021. The fair value of the May 2020 Warrant was determined using a Black Scholes model and included significant unobservable inputs such as volatility. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk free interest rate over the term. The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of September 30, 2021 and March 31, 2021 using a Black Scholes model: May 2020 Warrant May 2020 Warrants September 30, 2021 March 31, 2021 Stock price $ 1.03 $ 1.78 Volatility 89 % 78 % Remaining term (years) 2.51 3.01 Expected dividend yield — — Risk-free rate 0.41 % 0.35 % The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: September 30, 2021 Beginning balance, March 31, 2021 $ 1,931,921 Change in fair value of May 2020 Warrant liability (1,069,309 ) Ending balance, September 30, 2021 $ 862,612

Available-for-Sale-Securities

Available-for-Sale-Securities	6 Months Ended
	Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]
Available-for-Sale-Securities	Note 7. Available-for-Sale-Securities The following table summarizes available-for-sale securities recorded in cash and cash equivalents or marketable securities as of September 30, 2021: September 30, 2021 Amortized cost Gross Unrealized Gains Gross Unrealized Loss Fair Value Money market funds $ 6,726,462 $ — $ — $ 6,726,462 Corporate debt securities 23,683,402 381 (33,186 ) 23,650,597 Municipal debt securities 43,039,326 4,618 (30,370 ) 43,013,574 Total $ 73,449,190 $ 4,999 $ (63,556 ) $ 73,390,633 The following table summarizes the classification of available-for-sale securities: September 30, 2021 March 31, 2021 Cash and cash equivalents $ 6,726,462 $ — Marketable securities 66,664,171 — Total $ 73,390,633 $ — The following table summarizes our portfolio of available-for-sale securities by contractual maturity: Less than 12 months 12 months or Longer Total Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Money market funds $ 6,726,462 $ — $ — $ — $ 6,726,462 $ — Corporate debt securities 16,267,439 (18,012 ) 7,383,158 (14,793 ) 23,650,597 (32,805 ) Municipal debt securities 30,027,345 (9,837 ) 12,986,229 (15,915 ) 43,013,574 (25,752 ) Total $ 53,021,246 $ (27,849 ) $ 20,369,387 $ (30,708 ) $ 73,390,633 $ (58,557 )

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Equity	Note 8. Stockholders’ Equity Exchange Agreements On May 20, 2020, the Company entered into exchange agreements with holders (the “Holders”) of the warrants issued in April 2019 (the “April 2019 Warrants”). The April 2019 Warrants were offered and issued pursuant to the Company’s previous shelf registration statement on Form S-3 (File No. 333-211489). Pursuant to exchange agreements (the “Share Exchange Agreements”) with Holders of the April 2019 Warrants to purchase 5,833,333 shares of Common Stock in the aggregate, the Company issued an aggregate of 2,406,250 shares of common stock (the “Exchange Shares”) in exchange for such April 2019 Warrants. Concurrently therewith, each such Holder executed and delivered to the Company a leak-out agreement (a “Share Leak-Out Agreement”) that contained trading restrictions with respect to the Exchange Shares, which (i) for the first 90 days, prohibit any sales of Exchange Shares, (ii) for the subsequent 90 days, limit sales of Exchange Shares on any day to 2.5% of that day’s trading volume of Common Stock, and (iii) prohibit new short positions or short sales on Common Stock for the combined 180 day period. The Company also entered into an exchange agreement (the “Warrant Exchange Agreement”) with another Holder of April 2019 Warrants to purchase 2,166,667 shares of Common Stock in the aggregate. Pursuant to the Warrant Exchange Agreement, the Company issued such Holder a new warrant (the “May 2020 Warrant”) to purchase the same number of shares of Common Stock. The May 2020 Warrant has the same expiration date, April 2, 2024, as the April 2019 Warrants, but has an exercise price of $1.80 and does not include certain price protection, anti-dilution provisions or other restrictions on Company action from the April 2019 Warrants. Concurrently therewith, such Holder executed and delivered to the Company a leak-out agreement that contained trading restrictions on sales of Common Stock issued upon exercise of the May 2020 Warrant that are substantially similar to the restrictions on Exchange Shares in the Share Leak-Out Agreement, provided that the leak-out restrictions will only apply to the first 893,750 shares of Common Stock issued pursuant to the May 2020 Warrant. The April 2019 Warrants were remeasured as of May 20, 2020, before the exchange, using the Monte Carlo pricing simulation resulting in a fair value of approximately $7.3 million, and the change in fair value from March 31, 2020 to the fair value before the exchange of approximately $3.7 million was recorded as an expense component of other income (expense) within the condensed consolidated statement of operations. The key assumptions in applying the Monte Carlo simulation model were as follows: $1.70 stock price, 73% volatility, 3.87 years remaining term, 0.28% risk free rate and the probability of fundamental transactions occurring. At May 20, 2020, the fair value of the 2,406,250 shares issued under the Share Exchange Agreements was approximately $3.4 million and resulted in a gain on exchange of approximately $1.9 million. The exercise price of the May 2020 Warrant is subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s Common Stock. The Company determined that the May 2020 Warrant should be recorded as a derivative liability on the condensed consolidated balance sheet due to the May 2020 Warrant’s contractual provisions requiring issuance of registered common shares upon exercise. At May 20, 2020, the May 2020 Warrant was recorded at the fair value of $1.7 million as determined using the Black Scholes model and the change in fair value before and after the exchange of $0.3 million was recorded as a gain on warrant exchange as a component of other income (expense) within the condensed consolidated statement of operations. The key assumptions in applying the Black Scholes model were as follows: $1.64 stock price, 73% volatility, 3.87 years remaining term, 0.27% risk free rate and 7% discount for lack of marketability. The change in fair value of the May 2020 Warrant from May 20, 2020 through September 30, 2020 of $0.9 million income was recorded as a component of other income (expense) within the condensed consolidated statement of operations. The following summarizes the common stock warrant activity for the six months ended September 30, 2021: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2021 3,104,318 $ 2.77 Granted — — Exchanged — — Outstanding at September 30, 2021 3,104,318 $ 2.77 At each of September 30, 2021 and March 31, 2021, 3,074,551, of common stock purchase warrants relating to SPAs were outstanding and exercisable. Warrants The Company has warrants to purchase its common stock outstanding as of September 30, 2021, as follows: Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 May 2020 Liability 2,166,667 $ 1.80 April 2024 At-the-Market Financing Facility On October 18, 2019, the Company entered into the Sale Agreement with Jefferies, which was amended on August 12, 2020, pursuant to which the Company may, from time to time, sell shares of common stock, having an aggregate offering price of up to $30.0 million through Jefferies, as the Company’s sales agent. As indicated in the amendment, the shares will be offered and sold by the Company pursuant to its currently effective Registration Statement on Form S-3, as amended (Reg. No. 333-245033). Any sales of common stock pursuant to the Sales Agreement will be made by methods deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies will use commercially reasonable efforts to sell the shares from time to time, based on the instructions of the Company. The Company will pay Jefferies a commission rate of three percent (3%) of the gross proceeds from the sales of shares of Common Stock sold pursuant to the Sale Agreement. Under the Sale Agreement, the Company is not required to use the full available amount authorized and it may, by giving notice as specified in the Sale Agreement, terminate the Sale Agreement at any time The Company did not sell any shares through the Jefferies ATM during the six months ended September 30, 2021. During the six months ended September 30, 2020, the Company raised approximately $6.1 million in gross proceeds through the sale of 4,453,939 shares of Common Stock and incurred $0.3 million of related costs that offset the proceeds. At September 30, 2021, there remained approximately $22.2 million of availability to sell shares through the Jefferies ATM. Securities Purchase Agreement On January 7, 2020, the Company and Eagle entered into the Eagle SPA, pursuant to which the Company issued and sold to Eagle 10,000,000 shares of common stock, at a price of $2.00 per share. The Eagle SPA provides that Eagle will, subject to certain conditions, make an additional payment of $20 million upon the occurrence of a milestone event, which is defined as the earlier of ( i) achievement of the Registered Direct Offering On 2020

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Contract Service Providers In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. At September 30, 2021, the Company’s obligations to contract service providers, including PanCAN discussed below, were $3.2 million in the aggregate. On April 1, 2020, the Company amended the Clinical Research Funding and Drug Supply Agreement dated October 9, 2018, with PanCAN, to enroll individuals diagnosed with pancreatic cancer in a platform style clinical research study. Stage 1 of the study was initiated in the fourth quarter of fiscal year 2020. As of September 30, 2021, after taking into consideration amounts already incurred, the remaining expense to the Company is approximately $3.0 million, subject to enrollment adjustments, and is expected to be incurred over the next year. Purchase Commitments Legal Proceedings The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that it believes could have a material adverse effect on the Company, its business, operating results or financial condition. From time to time, the Company may be involved in litigation, claims or other contingencies arising in the ordinary course of business. The Company would accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company would not record a liability, but instead would disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such estimate can be made. Legal fees are expensed as incurred.

Leases

Leases	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Note 10. Leases The Company has a lease for office space in New Jersey, which expires in February 2023. Total Company rent expense, including short term rentals, was approximately $14,000 and $28,000 for the three and six months ended September 30, 2021 and $64,000 and $141,000 for the three and six months ended September 30, 2020. Operating lease ROU assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease ROU assets and liabilities. The Company uses its incremental borrowing rate of 11.0% to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable. As of September 30, 2021, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease ROU assets and lease liabilities were as follows: September 30, 2021 Fiscal year 2022 $ 19,620 Fiscal year 2023 43,164 Total remaining lease payments 62,784 Less: present value adjustment (4,634 ) Total operating lease liabilities 58,150 Less: current portion (38,883 ) Operating lease liabilities, net of current portion $ 19,267

Related Party Transactions

Related Party Transactions	6 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Legal Faegre Drinker Biddle & Reath (“Faegre Drinker”), formerly Drinker Biddle & Reath LLP (“DBR”), has provided legal services to the Company. The Company’s Chief Legal Officer and Corporate Secretary holds the consulting role “Senior Counsel” with Faegre Drinker. Legal fees incurred associated with Faegre Drinker were approximately $151,000 and $266,000 for the three and six months ended September 30, 2021, respectively, and $161,000 and $396,000 for the three and six months ended September 30, 2020. At September 30, 2021 and March 31, 2021, the Company had approximately $68,000 and $87,000, respectively, in accounts payable and accrued expenses payable to Faegre Drinker.

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	Note 12. Equity Incentive Plan Stock Options As of September 30, 2021, there was approximately $5.8 million of total unrecognized compensation expense related to non-vested stock options. The cost is expected to be recognized over the remaining weighted average service period of 3.1 years. As of September 30, 2021, there were 7,441,131 shares available for grant under the Company’s 2015 Equity Incentive Plan and 2016 Director Plan. Stock based compensation expense was recognized as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 General and administrative $ 480,000 $ 538,000 $ 951,000 $ 1,100,000 Research and development 136,000 346,000 309,000 853,000 Total $ 616,000 $ 884,000 $ 1,260,000 $ 1,953,000 The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. For employees and non-employees, the compensation expense is amortized on a straight-line basis over the requisite service period, which approximates the vesting period. The Company accounts for forfeitures as they occur, rather than estimating forfeitures as of an award’s grant date. The expected volatility of options granted has been determined using the method described under ASC 718 using the expected volatility of similar companies. The expected term of options granted to employees, non-employees and consultants in the current fiscal period has been based on the term by using the simplified method as allowed under SAB No. 110 and ASU 2018-7. The weighted average assumptions used to determine such values are presented in the following table: September 30, 2021 September 30, 2020 Risk free interest rate 0.28% - 1.01% 0.17% - 0.40% Expected volatility 97.11% - 105.37% 88.02% - 101.67% Expected term (in years) 2.7 - 6.1 2.8 - 6.1 Dividend yield 0 % 0 % The following is a summary of the status of the Company’s stock options for the six months ended September 30, 2021: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2021 12,588,068 $ 2.92 Granted 3,569,500 $ 1.38 Cancelled/Forfeited (1,453,870 ) $ 4.34 Exercised (6,250 ) $ 0.99 Outstanding at September 30, 2021 14,697,448 $ 2.40 Options exercisable at September 30, 2021 8,404,207 $ 3.23 Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at September 30, 2021 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at September 30, 2021 Weighted Average Exercise Price Aggregate Intrinsic Value $0.95 - $8.75 14,697,448 $ 2.40 7.5 $ 4,595 8,404,207 $ 3.23 $ 2,893 The intrinsic value calculated as the excess of the market value as of September 30, 2021 over the exercise price of the options is $ 4,595. The market value per share as of September 30, 2021 was $1.03 as reported by the NASDAQ Capital Market.

Income Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. The Company weighed available positive and negative evidence and concluded that a full valuation allowance should continue to be maintained on its net deferred tax assets. The Company is required to evaluate uncertain tax positions taken or expected to be taken in the course of preparing the Company’s condensed consolidated financial statements to determine whether the tax positions are more likely than not of being sustained by the applicable tax authority. As of September 30, 2021, the Company’s uncertain tax positions remain unchanged. Due to the full valuation allowance, none of the gross unrecognized tax benefits, if recognized, would affect the effective tax rate at September 30, 2021. The Company had no income tax related penalties or interest for periods presented in these condensed consolidated financial statements related to uncertain tax positions due to available net operating loss carryforwards, which would be recorded as tax expense should the Company accrue for such items.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 filed with the SEC on June 10, 2021 (the “2021 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiary, Tyme Inc. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in ASC and ASU of the FASB.
Principles of Consolidation	The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2021 included in the Company’s 2021 10-K.
Cash and Cash Equivalents	Cash and cash equivalents Cash and cash equivalents include demand deposit accounts, money market funds and municipal debt securities. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.
Marketable Securities	Marketable Securities All of the Company's marketable securities are debt securities and are classified as available-for-sale in accordance with the ASC Topic 320, “Investments - Debt and Equity Securities.” Available for sale securities are carried at fair value and reported in cash equivalents and marketable securities. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for a credit loss is recorded on our consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. Cash equivalents, marketable securities and the derivative warrant liability are recorded at fair value. Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets (Level 1), and the lowest priority to unobservable inputs (Level 3). The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and their applicability to the Company’s financial assets, are described below. Level 1 : Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. Level 2 : Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. Level 3 : Pricing inputs are unobservable for the assets. Level 3 assets include private investments that are supported by little or no market activity. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis see Note 6 .
Derivative Warrant Liability	Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise or certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the condensed consolidated statement of operations. As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features that cause the warrants to be treated as derivatives or requires the issuance of registered common shares upon exercise. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black-Scholes model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants (see Note 6).
Risks and Uncertainties	Risks and Uncertainties The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions The novel coronavirus (COVID-19) pandemic, and actions taken by governments and others to reduce its spread, has negatively impacted the global economy, financial markets, and the Company’s industry and has disrupted day-to-day life and business operations. Even as certain restrictions have been lifted, new processes implemented and vaccines have become more widely available and administered, spikes in infections (including the spread of new variants) continue to be experienced as conditions evolve and fluctuate around the world. The extent to which the continuing COVID-19 pandemic impacts our product candidates and business, including patients’ willingness to participate and remain in clinical trials, the timing of meeting enrollment expectations, the ability of our third-party partners to remain operational and our access to capital markets and financing sources, depends on numerous evolving factors that are highly uncertain, cannot be accurately predicted, and may be significant.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Income Taxes In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) The amendments in ASU No. 2020-06 are effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. FASB also specified that an entity should adopt the guidance as of the beginning of its annual fiscal year and is not permitted to adopt the guidance in an interim period. The Company adopted the pronouncement as of April 1, 2021 and the adoption of this standard did not have a material impact on its condensed consolidated financial statements and disclosures.
Fair Value Measurements	The Company’s financial instruments measured at fair value on a recurring basis as of September 30, 2021 and March 31, 2021 are as follows: Quoted prices in active markets Significant other observable inputs Significant unobservable inputs September 30, 2021 Total (Level 1) (Level 2) (Level 3) Financial assets Cash equivalents Money market funds $ 6,726,462 $ 6,726,462 $ — $ — Marketable Securities Short-term Corporate debt securities 16,267,438 — 16,267,438 — Municipal debt securities 30,027,345 — 30,027,345 — Long-term Corporate debt securities 7,383,159 — 7,383,159 — Municipal debt securities 12,986,229 — 12,986,229 — $ 73,390,633 $ 6,726,462 $ 66,664,171 $ — Financial liability Warrant liability $ 862,612 $ — $ — $ 862,612 March 31, 2021 Financial liability Warrant liability $ 1,931,921 $ — $ — $ 1,931,921 Fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The fair value of cash equivalents held in money market funds is determined based on “Level 1” inputs. Marketable securities classified as Level 2 within the valuation hierarchy consist of corporate debt securities and municipal debt securities. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The fair value measurement for the warrant issued in conjunction with the Exchange Agreements (see Note 8 for transaction details) (the “May 2020 Warrant”) is based on significant inputs not observable in the market and is classified as Level 3 liability as of September 30, 2021 and March 31, 2021. The fair value of the May 2020 Warrant was determined using a Black Scholes model and included significant unobservable inputs such as volatility. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk free interest rate over the term. The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of September 30, 2021 and March 31, 2021 using a Black Scholes model: May 2020 Warrant May 2020 Warrants September 30, 2021 March 31, 2021 Stock price $ 1.03 $ 1.78 Volatility 89 % 78 % Remaining term (years) 2.51 3.01 Expected dividend yield — — Risk-free rate 0.41 % 0.35 % The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: September 30, 2021 Beginning balance, March 31, 2021 $ 1,931,921 Change in fair value of May 2020 Warrant liability (1,069,309 ) Ending balance, September 30, 2021 $ 862,612
Stockholders' Equity	Stockholders’ Equity Exchange Agreements On May 20, 2020, the Company entered into exchange agreements with holders (the “Holders”) of the warrants issued in April 2019 (the “April 2019 Warrants”). The April 2019 Warrants were offered and issued pursuant to the Company’s previous shelf registration statement on Form S-3 (File No. 333-211489). Pursuant to exchange agreements (the “Share Exchange Agreements”) with Holders of the April 2019 Warrants to purchase 5,833,333 shares of Common Stock in the aggregate, the Company issued an aggregate of 2,406,250 shares of common stock (the “Exchange Shares”) in exchange for such April 2019 Warrants. Concurrently therewith, each such Holder executed and delivered to the Company a leak-out agreement (a “Share Leak-Out Agreement”) that contained trading restrictions with respect to the Exchange Shares, which (i) for the first 90 days, prohibit any sales of Exchange Shares, (ii) for the subsequent 90 days, limit sales of Exchange Shares on any day to 2.5% of that day’s trading volume of Common Stock, and (iii) prohibit new short positions or short sales on Common Stock for the combined 180 day period. The Company also entered into an exchange agreement (the “Warrant Exchange Agreement”) with another Holder of April 2019 Warrants to purchase 2,166,667 shares of Common Stock in the aggregate. Pursuant to the Warrant Exchange Agreement, the Company issued such Holder a new warrant (the “May 2020 Warrant”) to purchase the same number of shares of Common Stock. The May 2020 Warrant has the same expiration date, April 2, 2024, as the April 2019 Warrants, but has an exercise price of $1.80 and does not include certain price protection, anti-dilution provisions or other restrictions on Company action from the April 2019 Warrants. Concurrently therewith, such Holder executed and delivered to the Company a leak-out agreement that contained trading restrictions on sales of Common Stock issued upon exercise of the May 2020 Warrant that are substantially similar to the restrictions on Exchange Shares in the Share Leak-Out Agreement, provided that the leak-out restrictions will only apply to the first 893,750 shares of Common Stock issued pursuant to the May 2020 Warrant. The April 2019 Warrants were remeasured as of May 20, 2020, before the exchange, using the Monte Carlo pricing simulation resulting in a fair value of approximately $7.3 million, and the change in fair value from March 31, 2020 to the fair value before the exchange of approximately $3.7 million was recorded as an expense component of other income (expense) within the condensed consolidated statement of operations. The key assumptions in applying the Monte Carlo simulation model were as follows: $1.70 stock price, 73% volatility, 3.87 years remaining term, 0.28% risk free rate and the probability of fundamental transactions occurring. At May 20, 2020, the fair value of the 2,406,250 shares issued under the Share Exchange Agreements was approximately $3.4 million and resulted in a gain on exchange of approximately $1.9 million. The exercise price of the May 2020 Warrant is subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s Common Stock. The Company determined that the May 2020 Warrant should be recorded as a derivative liability on the condensed consolidated balance sheet due to the May 2020 Warrant’s contractual provisions requiring issuance of registered common shares upon exercise. At May 20, 2020, the May 2020 Warrant was recorded at the fair value of $1.7 million as determined using the Black Scholes model and the change in fair value before and after the exchange of $0.3 million was recorded as a gain on warrant exchange as a component of other income (expense) within the condensed consolidated statement of operations. The key assumptions in applying the Black Scholes model were as follows: $1.64 stock price, 73% volatility, 3.87 years remaining term, 0.27% risk free rate and 7% discount for lack of marketability. The change in fair value of the May 2020 Warrant from May 20, 2020 through September 30, 2020 of $0.9 million income was recorded as a component of other income (expense) within the condensed consolidated statement of operations. The following summarizes the common stock warrant activity for the six months ended September 30, 2021: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2021 3,104,318 $ 2.77 Granted — — Exchanged — — Outstanding at September 30, 2021 3,104,318 $ 2.77 At each of September 30, 2021 and March 31, 2021, 3,074,551, of common stock purchase warrants relating to SPAs were outstanding and exercisable. Warrants The Company has warrants to purchase its common stock outstanding as of September 30, 2021, as follows: Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 May 2020 Liability 2,166,667 $ 1.80 April 2024 At-the-Market Financing Facility On October 18, 2019, the Company entered into the Sale Agreement with Jefferies, which was amended on August 12, 2020, pursuant to which the Company may, from time to time, sell shares of common stock, having an aggregate offering price of up to $30.0 million through Jefferies, as the Company’s sales agent. As indicated in the amendment, the shares will be offered and sold by the Company pursuant to its currently effective Registration Statement on Form S-3, as amended (Reg. No. 333-245033). Any sales of common stock pursuant to the Sales Agreement will be made by methods deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies will use commercially reasonable efforts to sell the shares from time to time, based on the instructions of the Company. The Company will pay Jefferies a commission rate of three percent (3%) of the gross proceeds from the sales of shares of Common Stock sold pursuant to the Sale Agreement. Under the Sale Agreement, the Company is not required to use the full available amount authorized and it may, by giving notice as specified in the Sale Agreement, terminate the Sale Agreement at any time The Company did not sell any shares through the Jefferies ATM during the six months ended September 30, 2021. During the six months ended September 30, 2020, the Company raised approximately $6.1 million in gross proceeds through the sale of 4,453,939 shares of Common Stock and incurred $0.3 million of related costs that offset the proceeds. At September 30, 2021, there remained approximately $22.2 million of availability to sell shares through the Jefferies ATM. Securities Purchase Agreement On January 7, 2020, the Company and Eagle entered into the Eagle SPA, pursuant to which the Company issued and sold to Eagle 10,000,000 shares of common stock, at a price of $2.00 per share. The Eagle SPA provides that Eagle will, subject to certain conditions, make an additional payment of $20 million upon the occurrence of a milestone event, which is defined as the earlier of ( i) achievement of the Registered Direct Offering On 2020

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Basic and diluted net loss per common share calculation: Net loss $ (5,564,710 ) $ (6,850,534 ) $ (11,493,873 ) $ (15,676,349 ) Weighted average common shares outstanding — basic and diluted: 172,206,894 128,046,895 172,206,177 126,323,921 Net loss per share of common stock — basic and diluted $ (0.03 ) $ (0.05 ) $ (0.07 ) $ (0.12 )
Schedule of Anti-dilutive Shares Outstanding	The following outstanding securities at September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: September 30, 2021 2020 Stock options 14,697,448 14,577,732 Warrants 3,104,318 3,104,318 Total 17,801,766 17,682,050

Accounts Payable and Other Cu_2

Accounts Payable and Other Current Liabilities (Tables)	6 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Schedule of Accounts Payable and Other Current Liabilities	Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: September 30, 2021 March 31, 2021 Legal $ 147,596 $ 454,139 Consultant and professional services 65,679 176,957 Accounting and auditing 2,822 55,349 Research and development 2,662,905 2,657,202 Board of Directors and Scientific Advisory Board Compensation 429,281 435,594 Other 30,848 63,149 Total $ 3,339,131 $ 3,842,390

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The Company’s financial instruments measured at fair value on a recurring basis as of September 30, 2021 and March 31, 2021 are as follows: Quoted prices in active markets Significant other observable inputs Significant unobservable inputs September 30, 2021 Total (Level 1) (Level 2) (Level 3) Financial assets Cash equivalents Money market funds $ 6,726,462 $ 6,726,462 $ — $ — Marketable Securities Short-term Corporate debt securities 16,267,438 — 16,267,438 — Municipal debt securities 30,027,345 — 30,027,345 — Long-term Corporate debt securities 7,383,159 — 7,383,159 — Municipal debt securities 12,986,229 — 12,986,229 — $ 73,390,633 $ 6,726,462 $ 66,664,171 $ — Financial liability Warrant liability $ 862,612 $ — $ — $ 862,612 March 31, 2021 Financial liability Warrant liability $ 1,931,921 $ — $ — $ 1,931,921
Schedule of Key Inputs and Assumptions to Estimate the Fair Value of Warrant	The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of September 30, 2021 and March 31, 2021 using a Black Scholes model: May 2020 Warrant May 2020 Warrants September 30, 2021 March 31, 2021 Stock price $ 1.03 $ 1.78 Volatility 89 % 78 % Remaining term (years) 2.51 3.01 Expected dividend yield — — Risk-free rate 0.41 % 0.35 %
Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs	The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: September 30, 2021 Beginning balance, March 31, 2021 $ 1,931,921 Change in fair value of May 2020 Warrant liability (1,069,309 ) Ending balance, September 30, 2021 $ 862,612

Available-for-Sale-Securities (

Available-for-Sale-Securities (Tables)	6 Months Ended
	Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-Sale Securities Recorded In Cash and Cash Equivalents or Marketable Securities	The following table summarizes available-for-sale securities recorded in cash and cash equivalents or marketable securities as of September 30, 2021: September 30, 2021 Amortized cost Gross Unrealized Gains Gross Unrealized Loss Fair Value Money market funds $ 6,726,462 $ — $ — $ 6,726,462 Corporate debt securities 23,683,402 381 (33,186 ) 23,650,597 Municipal debt securities 43,039,326 4,618 (30,370 ) 43,013,574 Total $ 73,449,190 $ 4,999 $ (63,556 ) $ 73,390,633
Summary of Classification of Available-for-Sale Securities	The following table summarizes the classification of available-for-sale securities: September 30, 2021 March 31, 2021 Cash and cash equivalents $ 6,726,462 $ — Marketable securities 66,664,171 — Total $ 73,390,633 $ —
Summary of Available-for-Sale Securities By Contractual Maturity	The following table summarizes our portfolio of available-for-sale securities by contractual maturity: Less than 12 months 12 months or Longer Total Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Money market funds $ 6,726,462 $ — $ — $ — $ 6,726,462 $ — Corporate debt securities 16,267,439 (18,012 ) 7,383,158 (14,793 ) 23,650,597 (32,805 ) Municipal debt securities 30,027,345 (9,837 ) 12,986,229 (15,915 ) 43,013,574 (25,752 ) Total $ 53,021,246 $ (27,849 ) $ 20,369,387 $ (30,708 ) $ 73,390,633 $ (58,557 )

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Common Stock Warrant Activity	The following summarizes the common stock warrant activity for the six months ended September 30, 2021: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2021 3,104,318 $ 2.77 Granted — — Exchanged — — Outstanding at September 30, 2021 3,104,318 $ 2.77
Schedule of Warrants to Purchase Common Stock Outstanding	The Company has warrants to purchase its common stock outstanding as of September 30, 2021, as follows: Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 May 2020 Liability 2,166,667 $ 1.80 April 2024

Leases (Tables)

Leases (Tables)	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements	As of September 30, 2021, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease ROU assets and lease liabilities were as follows: September 30, 2021 Fiscal year 2022 $ 19,620 Fiscal year 2023 43,164 Total remaining lease payments 62,784 Less: present value adjustment (4,634 ) Total operating lease liabilities 58,150 Less: current portion (38,883 ) Operating lease liabilities, net of current portion $ 19,267

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	6 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock based compensation expense	Stock based compensation expense was recognized as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 General and administrative $ 480,000 $ 538,000 $ 951,000 $ 1,100,000 Research and development 136,000 346,000 309,000 853,000 Total $ 616,000 $ 884,000 $ 1,260,000 $ 1,953,000
Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted	The weighted average assumptions used to determine such values are presented in the following table: September 30, 2021 September 30, 2020 Risk free interest rate 0.28% - 1.01% 0.17% - 0.40% Expected volatility 97.11% - 105.37% 88.02% - 101.67% Expected term (in years) 2.7 - 6.1 2.8 - 6.1 Dividend yield 0 % 0 %
Schedule of Stock Options	The following is a summary of the status of the Company’s stock options for the six months ended September 30, 2021: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2021 12,588,068 $ 2.92 Granted 3,569,500 $ 1.38 Cancelled/Forfeited (1,453,870 ) $ 4.34 Exercised (6,250 ) $ 0.99 Outstanding at September 30, 2021 14,697,448 $ 2.40 Options exercisable at September 30, 2021 8,404,207 $ 3.23
Schedule of Stock Option by Exercise Price Range	Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at September 30, 2021 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at September 30, 2021 Weighted Average Exercise Price Aggregate Intrinsic Value $0.95 - $8.75 14,697,448 $ 2.40 7.5 $ 4,595 8,404,207 $ 3.23 $ 2,893

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($)	Feb. 08, 2021	Jan. 07, 2020	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Oct. 18, 2019
Nature Of Business [Line Items]
Estimated close out trial costs							$ 843,000
Close out trial costs expected to be incurred over next nine months			$ 1,200,000				1,200,000
Net cash used in operating activities							(10,280,351)	$ (12,764,099)
Net loss			(5,564,710)	$ (5,929,163)	$ (6,850,534)	$ (8,825,815)	(11,493,873)	(15,676,349)
Non-cash equity compensation							1,259,892	1,952,625
Working capital			72,600,000				72,600,000
Net amortization expense of premiums and discounts on marketable securities							(722,493)
Non-cash expenses related to change in fair value of warrant liability			(344,166)		$ (489,572)		$ (1,069,309)	$ 2,773,699
Registered Direct Offering [Member]
Nature Of Business [Line Items]
Proceeds from issuance of common stock	$ 100,000,000
Related cost offset the proceeds	$ 6,200,000
Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]
Nature Of Business [Line Items]
Share price (in dollars per share)		$ 2
Sale Agreement [Member] | Jefferies [Member]
Nature Of Business [Line Items]
Number of shares issued upon new issue							0	4,453,939
Proceeds from issuance of common stock								$ 6,100,000
Related cost offset the proceeds								300,000
Offering expense								$ 300,000
Available for offering			$ 22,200,000				$ 22,200,000
Sale Agreement [Member] | Jefferies [Member] | Maximum [Member]
Nature Of Business [Line Items]
Aggregate offering									$ 30,000,000
Common Stock [Member] | Registered Direct Offering [Member]
Nature Of Business [Line Items]
Number of shares issued upon new issue	40,000,000
Share price (in dollars per share)	$ 2.50
Common Stock [Member] | Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]
Nature Of Business [Line Items]
Number of shares issued upon new issue		10,000,000
Share price (in dollars per share)		$ 2
Proceeds from issuance of common stock		$ 20,000,000

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)	Sep. 30, 2021
Accounting Standards Update 2019-12 [Member]
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Apr. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect	true
Accounting Standards Update 2016-13 [Member]
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Apr. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect	true
Accounting Standards Update 2020-06 [Member]
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Apr. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect	true

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)	3 Months Ended				6 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Basic and diluted net loss per common share calculation:
Net loss	$ (5,564,710)	$ (5,929,163)	$ (6,850,534)	$ (8,825,815)	$ (11,493,873)	$ (15,676,349)
Weighted average common shares outstanding — basic and diluted:	172,206,894		128,046,895		172,206,177	126,323,921
Net loss per share of common stock — basic and diluted	$ (0.03)		$ (0.05)		$ (0.07)	$ (0.12)

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Anti-dilutive Shares Outstanding (Detail) - shares	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	17,801,766	17,682,050
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	14,697,448	14,577,732
Warrant [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	3,104,318	3,104,318

Accounts Payable and Other Cu_3

Accounts Payable and Other Current Liabilities - Schedule of Accounts Payable and Other Current Liabilities (Detail) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Payables And Accruals [Abstract]
Legal	$ 147,596	$ 454,139
Consultant and professional services	65,679	176,957
Accounting and auditing	2,822	55,349
Research and development	2,662,905	2,657,202
Board of Directors and Scientific Advisory Board Compensation	429,281	435,594
Other	30,848	63,149
Total	$ 3,339,131	$ 3,842,390

Severance Payable - Additional

Severance Payable - Additional Information (Detail) $ in Millions	Mar. 15, 2019	Sep. 30, 2021USD ($)Employee	Mar. 31, 2019USD ($)	Mar. 31, 2021USD ($)
Severance Payable [Line Items]
Number of employees entered into separation and general agreement | Employee		2
Salary continuance term	5 years
Reimbursement of health benefits term	3 years
Severance expense			$ 2.5
Discount rate			6.00%
Stock option modification expense			$ 0.4
Severance liability		$ 1.3		$ 1.6
Minimum [Member]
Severance Payable [Line Items]
Post-termination exercise period	3 months
Maximum [Member]
Severance Payable [Line Items]
Post-termination exercise period	5 years

Fair Value of Financial Instrum

Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	$ 6,726,462
Marketable securities	46,294,783
Marketable securities	20,369,388
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets	73,390,633
Warrant liability	862,612	$ 1,931,921
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	16,267,438
Marketable securities	7,383,159
Fair Value, Measurements, Recurring [Member] | Municipal Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	30,027,345
Marketable securities	12,986,229
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	6,726,462
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets	6,726,462
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	6,726,462
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets	66,664,171
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	16,267,438
Marketable securities	7,383,159
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Municipal Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	30,027,345
Marketable securities	12,986,229
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	$ 862,612	$ 1,931,921

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Schedule of Key Inputs and Assumption to Estimate the Fair Value of Warrant (Detail) - Warrant [Member] - Class Of Warrant Or Right Issued on May 2020 [Member]	Sep. 30, 2021	Mar. 31, 2021
Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.0103	0.0178
Volatility [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.89	0.78
Remaining Term [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	2 years 6 months 3 days	3 years 3 days
Risk-free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.0041	0.0035

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of warrant liability	$ (344,166)	$ (489,572)	$ (1,069,309)	$ 2,773,699
May 2020 Warrant Liability [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning balance, March 31, 2021			1,931,921
Change in fair value of warrant liability			(1,069,309)
Ending balance, September 30, 2021	$ 862,612		$ 862,612

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-Sale Securities Recorded In Cash and Cash Equivalents or Marketable Securities (Detail)	Sep. 30, 2021USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	$ 73,449,190
Gross Unrealized Gains	4,999
Gross Unrealized Loss	(63,556)
Fair Value	73,390,633
Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	6,726,462
Fair Value	6,726,462
Corporate Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	23,683,402
Gross Unrealized Gains	381
Gross Unrealized Loss	(33,186)
Fair Value	23,650,597
Municipal Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	43,039,326
Gross Unrealized Gains	4,618
Gross Unrealized Loss	(30,370)
Fair Value	$ 43,013,574

Available-for-Sale Securities_2

Available-for-Sale Securities - Summary of Classification of Available-for-Sale Securities (Detail)	Sep. 30, 2021USD ($)
Investments Debt And Equity Securities [Abstract]
Cash equivalents	$ 6,726,462
Marketable securities	66,664,171
Total	$ 73,390,633

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Available-for-Sale Securities By Contractual Maturity (Detail)	Sep. 30, 2021USD ($)
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	$ 53,021,246
Less than 12 months, Net Unrealized Losses	(27,849)
12 months or Longer, Fair Value	20,369,387
12 months or Longer, Net Unrealized Losses	(30,708)
Total	73,390,633
Total, Net Unrealized Losses	(58,557)
Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	6,726,462
Total	6,726,462
Corporate Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	16,267,439
Less than 12 months, Net Unrealized Losses	(18,012)
12 months or Longer, Fair Value	7,383,158
12 months or Longer, Net Unrealized Losses	(14,793)
Total	23,650,597
Total, Net Unrealized Losses	(32,805)
Municipal Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	30,027,345
Less than 12 months, Net Unrealized Losses	(9,837)
12 months or Longer, Fair Value	12,986,229
12 months or Longer, Net Unrealized Losses	(15,915)
Total	43,013,574
Total, Net Unrealized Losses	$ (25,752)

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Feb. 08, 2021USD ($)$ / sharesshares	May 20, 2020USD ($)$ / sharesshares	Jan. 07, 2020USD ($)$ / sharesshares	Oct. 18, 2019USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)shares	Mar. 31, 2021$ / sharesshares
Stockholders Equity [Line Items]
Change in fair value of warrant liability					$ (344,166)	$ (489,572)		$ (1,069,309)	$ 2,773,699
Gain on warrant exchange									$ 2,228,697
Common stock, par value (in dollars per share) | $ / shares					$ 0.0001			$ 0.0001		$ 0.0001
Sale Agreement [Member] | Jefferies [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue | shares								0	4,453,939
Payment of commission rate from gross proceeds				3.00%
Available for offering					$ 22,200,000			$ 22,200,000
Proceeds from issuance of common stock									$ 6,100,000
Related cost offset the proceeds									$ 300,000
Sale Agreement [Member] | Jefferies [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Aggregate offering				$ 30,000,000
Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]
Stockholders Equity [Line Items]
Common stock price per share | $ / shares			$ 2
Milestone payments upon occurrence of milestone event payable			$ 20,000,000
Milestone payments upon occurrence of milestone event payable in cash			10,000,000
Milestone payments upon occurrence of milestone event payable in shares			$ 10,000,000
Milestone payments upon occurrence of milestone event payable in shares, Percentage of premium over share price			15.00%
Restricted period for Sale of shares description			shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement
Registered Direct Offering [Member]
Stockholders Equity [Line Items]
Proceeds from issuance of common stock	$ 100,000,000
Related cost offset the proceeds	$ 6,200,000
Common Stock [Member] | Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue | shares			10,000,000
Proceeds from issuance of common stock			$ 20,000,000
Common stock price per share | $ / shares			$ 2
Common Stock [Member] | Registered Direct Offering [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue | shares	40,000,000
Common stock price per share | $ / shares	$ 2.50
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Common Stock [Member] | Class Of Warrant Or Right Issued on May 2020 [Member]
Stockholders Equity [Line Items]
Exercise price | $ / shares					$ 1.80			$ 1.80
Share Exchange Agreements [Member]
Stockholders Equity [Line Items]
Number of shares that can be purchased with warrants | shares		5,833,333
Share leak-out agreement trading restrictions on exchange shares description								trading restrictions with respect to the Exchange Shares, which (i) for the first 90 days, prohibit any sales of Exchange Shares, (ii) for the subsequent 90 days, limit sales of Exchange Shares on any day to 2.5% of that day’s trading volume of Common Stock, and (iii) prohibit new short positions or short sales on Common Stock for the combined 180 day period.
Fair value of warrants		$ 3,400,000
Gain on warrant exchange		$ 1,900,000
Share Exchange Agreements [Member] | Common Stock [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue | shares		2,406,250
Warrant Exchange Agreements [Member]
Stockholders Equity [Line Items]
Number of shares that can be purchased with warrants | shares		2,166,667
Warrants expiration date		Apr. 2, 2024
Exercise price | $ / shares		$ 1.80
Number of common stock shares applicable for leak-out restrictions under leak-out agreement | shares		893,750
Fair value of warrants		$ 7,300,000
Warrant Exchange Agreements [Member] | Other Income (Expense) [Member]
Stockholders Equity [Line Items]
Change in fair value of warrant liability		3,700,000					$ (900,000)
Gain on warrant exchange		300,000
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued on May 2020 [Member]
Stockholders Equity [Line Items]
Fair value of warrants		$ 1,700,000
Warrant Exchange Agreements [Member] | Stock Price [Member] | Class Of Warrant Or Right Issued on April 2019 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		0.0170
Warrant Exchange Agreements [Member] | Stock Price [Member] | Class Of Warrant Or Right Issued on May 2020 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		0.0164
Warrant Exchange Agreements [Member] | Volatility [Member] | Class Of Warrant Or Right Issued on April 2019 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		0.73
Warrant Exchange Agreements [Member] | Volatility [Member] | Class Of Warrant Or Right Issued on May 2020 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		0.73
Warrant Exchange Agreements [Member] | Remaining Term [Member] | Class Of Warrant Or Right Issued on April 2019 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		3 years 10 months 13 days
Warrant Exchange Agreements [Member] | Remaining Term [Member] | Class Of Warrant Or Right Issued on May 2020 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		3 years 10 months 13 days
Warrant Exchange Agreements [Member] | Risk-free Interest Rate [Member] | Class Of Warrant Or Right Issued on April 2019 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		0.0028
Warrant Exchange Agreements [Member] | Risk-free Interest Rate [Member] | Class Of Warrant Or Right Issued on May 2020 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		0.0027
Warrant Exchange Agreements [Member] | Discount for Lack of Marketability [Member] | Class Of Warrant Or Right Issued on May 2020 [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Fair value assumptions		0.07
Securities Purchase Agreement [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Common stock purchase warrants outstanding and exercisable | shares					3,074,551			3,074,551		3,074,551

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Detail)	Sep. 30, 2021$ / sharesshares
Equity [Abstract]
Warrant Shares of Common Stock, Outstanding at beginning | shares	3,104,318
Warrant Shares of Common Stock, Outstanding at ending | shares	3,104,318
Weighted Average Exercise Price, Outstanding at beginning | $ / shares	$ 2.77
Weighted Average Exercise Price, Outstanding at ending | $ / shares	$ 2.77

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Detail) - $ / shares	6 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	3,104,318	3,104,318
Class Of Warrant Or Right Issued on December 2015 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2015-12
Classification	Equity
Warrants Outstanding	446,500
Exercise Price	$ 5
Expiration	2025-12
Class Of Warrant Or Right Issued on February 2016 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2016-02
Classification	Equity
Warrants Outstanding	461,384
Exercise Price	$ 5
Expiration	2026-02
Class Of Warrant Or Right Issued on July 2016 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2016-07
Classification	Equity
Warrants Outstanding	29,767
Exercise Price	$ 5
Expiration	2026-06
Class Of Warrant Or Right Issued on May 2020 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2020-05
Classification	Liability
Warrants Outstanding	2,166,667
Exercise Price	$ 1.80
Expiration	2024-04

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Commitment And Contingencies [Line Items]
Research study expense	$ 3,495,416	$ 4,707,448	$ 7,679,827	$ 9,422,743
Ongoing Clinical Trials [Member]
Commitment And Contingencies [Line Items]
Contractual obligation	800,000		800,000
Clinical Registration Activity [Member]
Commitment And Contingencies [Line Items]
Contractual obligation	$ 3,200,000		3,200,000
Clinical Research Funding and Drug Supply Agreement [Member] | Pancreatic Cancer Action Network [Member]
Commitment And Contingencies [Line Items]
Research study expense			$ 3,000,000
Research study expense expected to be incurred			1 year

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Lessee Lease Description [Line Items]
Rent expense	$ 14,000	$ 64,000	$ 28,000	$ 141,000
Incremental borrowing rate to calculate present value of lease payments	11.00%		11.00%
New Jersey [Member] | Office Space [Member]
Lessee Lease Description [Line Items]
Operating lease, expiration term			2023-02

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements (Detail) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Operating Lease Liabilities Payments Due [Abstract]
Fiscal year 2022	$ 19,620
Fiscal year 2023	43,164
Total remaining lease payments	62,784
Less: present value adjustment	(4,634)
Total operating lease liabilities	58,150
Less: current portion	(38,883)	$ (34,658)
Operating lease liabilities, net of current portion	$ 19,267	$ 41,256

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Faegre Drinker Biddle & Reath (“Faegre Drinker") [Member] - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021
Related Party Transaction [Line Items]
Legal fees	$ 151,000	$ 161,000	$ 266,000	$ 396,000
Accounts payable and accrued expenses payable	$ 68,000		$ 68,000		$ 87,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Detail)	6 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 5,800,000
Unrecognized compensation expense recognition period	3 years 1 month 6 days
2015 Equity Incentive Plan and 2016 Director Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grants | shares	7,441,131
Equity Incentive Plan 2015 and 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, options	$ 4,595
Share price (in dollars per share) | $ / shares	$ 1.03

Equity Incentive Plan - Allocat

Equity Incentive Plan - Allocation of Share Based Compensation (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 616,000	$ 884,000	$ 1,260,000	$ 1,953,000
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	480,000	538,000	951,000	1,100,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 136,000	$ 346,000	$ 309,000	$ 853,000

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted (Detail)	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Summary Of Stock Option Activities [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	0.28%	0.17%
Expected volatility	97.11%	88.02%
Expected term (in years)	2 years 8 months 12 days	2 years 9 months 18 days
Maximum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	1.01%	0.40%
Expected volatility	105.37%	101.67%
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Stock Options (Detail)	6 Months Ended
	Sep. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning | shares	12,588,068
Granted | shares	3,569,500
Cancelled/Forfeited | shares	(1,453,870)
Exercised | shares	(6,250)
Outstanding at ending | shares	14,697,448
Options exercisable | shares	8,404,207
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning | $ / shares	$ 2.92
Granted | $ / shares	1.38
Cancelled/Forfeited | $ / shares	4.34
Exercised | $ / shares	0.99
Outstanding at ending | $ / shares	2.40
Options exercisable | $ / shares	$ 3.23

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of Stock Option by Exercise Price Range (Detail) - USD ($)	6 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Stock Options Outstanding
Weighted Average Exercise Price	$ 2.40	$ 2.92
Exercise Price $0.98 - $8.75 [Member]
Stock Options Outstanding
Range of Exercise Price, Lower Limit	0.95
Range of Exercise Price, Upper Limit	$ 8.75
Number Outstanding	14,697,448
Weighted Average Exercise Price	$ 2.40
Weighted Average Remaining Life (Years)	7 years 6 months
Aggregate Intrinsic Value	$ 4,595
Stock Options Vested
Stock Options Vested	8,404,207
Weighted Average Exercise Price	$ 3.23
Aggregate Intrinsic Value	$ 2,893